Bora CDMO Bora CDMO

X

Find Milrinone Lactate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass
Related ProductsRelated Products
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

0

API REF. PRICE (USD / KG)
INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

0

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Milrinone Lactate
Also known as: 100286-97-3, 9k8xr81mo8, 6-methyl-2-oxo-5-pyridin-4-yl-1h-pyridine-3-carbonitrile lactate, 2-hydroxypropanoic acid;6-methyl-2-oxo-5-pyridin-4-yl-1h-pyridine-3-carbonitrile, Chebi:34850, Unii-9k8xr81mo8
Molecular Formula
C15H15N3O4
Molecular Weight
301.30  g/mol
InChI Key
VWUPWEAFIOQCGF-UHFFFAOYSA-N
FDA UNII
9K8XR81MO8

A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase type 3 activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the inotropic potency of amrinone.
1 2D Structure

Milrinone Lactate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-hydroxypropanoic acid;6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile
2.1.2 InChI
InChI=1S/C12H9N3O.C3H6O3/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8;1-2(4)3(5)6/h2-6H,1H3,(H,15,16);2,4H,1H3,(H,5,6)
2.1.3 InChI Key
VWUPWEAFIOQCGF-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2.CC(C(=O)O)O
2.2 Other Identifiers
2.2.1 UNII
9K8XR81MO8
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Corotrop

2. Corotrope

3. Lactate, Milrinone

4. Milrinone

5. Primacor

6. Win 47203

7. Win-47203

8. Win47203

2.3.2 Depositor-Supplied Synonyms

1. 100286-97-3

2. 9k8xr81mo8

3. 6-methyl-2-oxo-5-pyridin-4-yl-1h-pyridine-3-carbonitrile Lactate

4. 2-hydroxypropanoic Acid;6-methyl-2-oxo-5-pyridin-4-yl-1h-pyridine-3-carbonitrile

5. Chebi:34850

6. Unii-9k8xr81mo8

7. Milrinonelactate

8. Milrinone Lactose In 5% Dextrose

9. Primacor (tn)

10. Primacor In Dextrose 5% In Plastic Container

11. Milrinone Lactate [mi]

12. Milrinone Lactate In 5% Dextrose In Plastic Container

13. Chembl1200977

14. Milrinone Lactate [vandf]

15. Milrinone Lactate [mart.]

16. Milrinone Lactate In Dextrose 5% In Plastic Container

17. Milrinone Lactate [who-dd]

18. Akos015917733

19. Milrinone Lactate [orange Book]

20. 1,6-dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile, Compd. With 2-hydroxypropionic Acid

21. Ls-14389

22. Ft-0739660

23. D02085

24. 286m973

25. A897507

26. Q27116295

27. 2-[(4-chlorobenzyl)sulfanyl]benzenecarboxylicacid

28. 1,6-dihydro-2-methyl-6-oxo[3,4'-bipyridine]-5-carbonitrile Lactate

29. 2-hydroxypropanoic Acid,6-methyl-2-oxo-5-pyridin-4-yl-1h-pyridine-3-carbonitrile

30. 6-methyl-2-oxo-5-pyridin-4-yl-1h-pyridine-3-carbonitrile 2-hydroxypropanoic Acid

31. Hydron;2-hydroxypropanoate;6-methyl-2-oxo-5-pyridin-4-yl-1h-pyridine-3-carbonitrile

32. Propanoic Acid, 2-hydroxy-, Compd. With 1,6-dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile

2.4 Create Date
2005-06-24
3 Chemical and Physical Properties
Molecular Weight 301.30 g/mol
Molecular Formula C15H15N3O4
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count6
Rotatable Bond Count2
Exact Mass301.10625597 g/mol
Monoisotopic Mass301.10625597 g/mol
Topological Polar Surface Area123 Ų
Heavy Atom Count22
Formal Charge0
Complexity478
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameMilrinone lactate
Drug LabelMilrinone Lactate Injection is a member of a new class of bipyridine inotropic/vasodilator agents with phosphodiesterase inhibitor activity, distinct from digitalis glycosides or catecholamines. Milrinone lactate is designated chemically as 1,6-Dihyd...
Active IngredientMilrinone lactate
Dosage FormInjectable
Routeinjection; Injection
Strength20mg/20ml; eq 1mg base/ml; eq 20mg /20ml (1mg/ml); eq 50mg /50ml (1mg/ml)
Market StatusPrescription
CompanyBedford; Hospira; Gland Pharma; Apotex; Hikma Farmaceutica; Fresenius Kabi Usa; Hikma Maple; Intl Medicated

2 of 2  
Drug NameMilrinone lactate
Drug LabelMilrinone Lactate Injection is a member of a new class of bipyridine inotropic/vasodilator agents with phosphodiesterase inhibitor activity, distinct from digitalis glycosides or catecholamines. Milrinone lactate is designated chemically as 1,6-Dihyd...
Active IngredientMilrinone lactate
Dosage FormInjectable
Routeinjection; Injection
Strength20mg/20ml; eq 1mg base/ml; eq 20mg /20ml (1mg/ml); eq 50mg /50ml (1mg/ml)
Market StatusPrescription
CompanyBedford; Hospira; Gland Pharma; Apotex; Hikma Farmaceutica; Fresenius Kabi Usa; Hikma Maple; Intl Medicated

5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Cardiotonic Agents

Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)


Phosphodiesterase 3 Inhibitors

Compounds that specifically inhibit PHOSPHODIESTERASE 3. (See all compounds classified as Phosphodiesterase 3 Inhibitors.)


Vasodilator Agents

Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)


Platelet Aggregation Inhibitors

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)


5.2 FDA Pharmacological Classification
5.2.1 Pharmacological Classes
Phosphodiesterase 3 Inhibitors [MoA]; Phosphodiesterase 3 Inhibitor [EPC]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY